| __timestamp | Galapagos NV | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 111110000 | 14400000 |
| Thursday, January 1, 2015 | 129714000 | 33800000 |
| Friday, January 1, 2016 | 139574000 | 35900000 |
| Sunday, January 1, 2017 | 218502000 | 1254000 |
| Monday, January 1, 2018 | 322876000 | 4889000 |
| Tuesday, January 1, 2019 | 427320000 | 7400000 |
| Wednesday, January 1, 2020 | 523667000 | 10100000 |
| Friday, January 1, 2021 | 1629000 | 14300000 |
| Saturday, January 1, 2022 | 12079000 | 23200000 |
| Sunday, January 1, 2023 | 35989000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Unleashing insights
In the competitive world of biotechnology, cost management is crucial for success. This chart compares the cost of revenue for Neurocrine Biosciences, Inc. and Galapagos NV from 2014 to 2023. Over this period, Galapagos NV experienced a significant increase in cost of revenue, peaking in 2020 with a staggering 370% rise from 2014. In contrast, Neurocrine Biosciences, Inc. maintained a more stable trajectory, with costs increasing by approximately 175% over the same period. Notably, 2021 marked a dramatic drop for Galapagos NV, with costs plummeting to just 1% of their 2020 peak. This fluctuation highlights the volatile nature of the biotech industry, where strategic decisions and market conditions can dramatically impact financial outcomes. As we look to the future, these trends offer valuable insights into the financial strategies of these two industry leaders.
Johnson & Johnson vs Galapagos NV: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Merck & Co., Inc. and Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Catalent, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Exelixis, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Insmed Incorporated and Galapagos NV
Comparing Cost of Revenue Efficiency: Catalent, Inc. vs Galapagos NV
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Galapagos NV
Cost of Revenue Trends: Travere Therapeutics, Inc. vs Galapagos NV